During the JPMorgan Healthcare Conference, Xingli Wang, Co-President of Fosun Pharma, spoke with Endpoints News about the company’s long-term direction and its goal of building a global biopharmaceutical organization.
In the interview, he discussed the company’s focus on developing, launching, and commercializing innovative medicines worldwide, with continued investment across oncology, autoimmune, and neurodegenerative diseases — supported by growing capabilities in key markets, including the United States.
Fosun Pharma USA plays a key role in this effort, helping advance global innovation through U.S.-based development, regulatory, and commercial work, with a focus on delivering meaningful impact for patients.
Read the full interview here:
https://lnkd.in/g2jdhCZD
